225 related articles for article (PubMed ID: 27666119)
1. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y
Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S; Bayerlová M; Vetter M; Wachter A; Mitra D; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Thomssen C; Korf U; Beissbarth T; Wiemann S; Kantelhardt EJ
Breast Cancer Res; 2017 Oct; 19(1):112. PubMed ID: 29020998
[TBL] [Abstract][Full Text] [Related]
3. High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients.
Shi H; Fang X; Li Y; Zhang Y
Med Sci Monit; 2019 Oct; 25():7430-7438. PubMed ID: 31581160
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma.
Wang B; Wang W; Zhu Z; Zhang X; Tang F; Wang D; Liu X; Yan X; Zhuang H
Clin Neurol Neurosurg; 2017 Mar; 154():28-33. PubMed ID: 28107674
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
6. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.
Bleckmann A; Conradi LC; Menck K; Schmick NA; Schubert A; Rietkötter E; Arackal J; Middel P; Schambony A; Liersch T; Homayounfar K; Beißbarth T; Klemm F; Binder C; Pukrop T
Clin Exp Metastasis; 2016 Apr; 33(4):309-23. PubMed ID: 26862065
[TBL] [Abstract][Full Text] [Related]
7. ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption.
Li X; Zhang K; Hu Y; Luo N
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894856
[TBL] [Abstract][Full Text] [Related]
8. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
9. High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors.
Liu Y; Yin C; Deng MM; Wang Q; He XQ; Li MT; Li CP; Wu H
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9379-9392. PubMed ID: 31773687
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the clinical significance of SHMT2 and its co-expressed gene in human kidney cancer.
Wang H; Chong T; Li BY; Chen XS; Zhen WB
Biol Res; 2020 Oct; 53(1):46. PubMed ID: 33066813
[TBL] [Abstract][Full Text] [Related]
11. Cancer proteome and metabolite changes linked to SHMT2.
Tong J; Krieger JR; Taylor P; Bagshaw R; Kang J; Jeedigunta S; Wybenga-Groot LE; Zhang W; Badr H; Mirhadi S; Pham NA; Coyaud É; Yu M; Li M; Cabanero M; Raught B; Maynes JT; Hawkins C; Tsao MS; Moran MF
PLoS One; 2020; 15(9):e0237981. PubMed ID: 32903271
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHMT2 as a Potential Prognostic Biomarker and Correlating with Immune Infiltrates in Lung Adenocarcinoma.
Luo L; Zheng Y; Lin Z; Li X; Li X; Li M; Cui L; Luo H
J Immunol Res; 2021; 2021():6647122. PubMed ID: 33928169
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
[TBL] [Abstract][Full Text] [Related]
15. Serine Catabolism by SHMT2 Is Required for Proper Mitochondrial Translation Initiation and Maintenance of Formylmethionyl-tRNAs.
Minton DR; Nam M; McLaughlin DJ; Shin J; Bayraktar EC; Alvarez SW; Sviderskiy VO; Papagiannakopoulos T; Sabatini DM; Birsoy K; Possemato R
Mol Cell; 2018 Feb; 69(4):610-621.e5. PubMed ID: 29452640
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of mitochondrial serine hydroxyl-methyltransferase 2 is associated with poor prognosis and promotes cell proliferation and invasion in gliomas.
Wu M; Wanggou S; Li X; Liu Q; Xie Y
Onco Targets Ther; 2017; 10():3781-3788. PubMed ID: 28794642
[TBL] [Abstract][Full Text] [Related]
17. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis.
Wei Z; Song J; Wang G; Cui X; Zheng J; Tang Y; Chen X; Li J; Cui L; Liu CY; Yu W
Nat Commun; 2018 Oct; 9(1):4468. PubMed ID: 30367038
[TBL] [Abstract][Full Text] [Related]
18. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
19. SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Ning S; Ma S; Saleh AQ; Guo L; Zhao Z; Chen Y
Gastroenterol Res Pract; 2018; 2018():4369253. PubMed ID: 30228815
[TBL] [Abstract][Full Text] [Related]
20. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
